Page 1 of 28912345...102030...Last »


Hematology – Physiology – Part 1 – Video



Hematology – Physiology – Part 1
Hematology – Physiology – Part 1 Lecture series by G. Fuller, who has been teaching Physiology course for 35 years. This was the last semester teaching befor…

By: Wizard of Science

Read the original post:
Hematology – Physiology – Part 1 – Video

Hematology – Physiology – Part 4 – Video



Hematology – Physiology – Part 4
Hematology – Physiology – Part 3 Lecture series by G. Fuller, who has been teaching Physiology course for 35 years. This was the last semester teaching befor…

By: Wizard of Science

Excerpt from:
Hematology – Physiology – Part 4 – Video

Psoriasis and Ayurvedic Treatment by Prof Dr Murali Manohar Chirumamilla M.D. (Ayurveda) – Video



Psoriasis and Ayurvedic Treatment by Prof Dr Murali Manohar Chirumamilla M.D. (Ayurveda)
For Details, please visit : E mail : muralimanoharch@hotmail.com In-depth health education videos in Telugu about various disea. Ayurvedic Treatment For Psor…

By: Glennie Donovan

See the original post:
Psoriasis and Ayurvedic Treatment by Prof Dr Murali Manohar Chirumamilla M.D. (Ayurveda) – Video

Research and Markets: Global Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Pipeline Review 2014 – Analysis of 42 …

Research and Markets has announced the addition of the "Plaque Psoriasis – Pipeline Review

Read more:
Research and Markets: Global Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Pipeline Review 2014 – Analysis of 42 …

Pfizer Announces Positive Top-Line Results from Two Phase 3 Trials of Tofacitinib in Adults with Moderate-to-Severe …

Pfizer Inc. announced today top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials Program, OPT Pivotal #1 and OPT Pivotal #2 , evaluating the efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, the first in a new class of medicines being investigated for the treatment of moderate-to-severe plaque psoriasis.

Excerpt from:
Pfizer Announces Positive Top-Line Results from Two Phase 3 Trials of Tofacitinib in Adults with Moderate-to-Severe …

Psoriasis drug meets primary endpoints

Pfizer's ( PFE ) Janus kinase inhibitor XELJANZ (tobacitinib), a twice-daily oral pill for the treatment of moderate-to-severe plaque psoriasis, meets its primary endpoints in two Phase 3 clinical trials, OPT#1 and OPT#2. The primary efficacy endpoints were a statistically significant superiority over placebo at week 16 in the proportion of patients achieving a Physicians Global Assessment …

Continue reading here:
Psoriasis drug meets primary endpoints

Pfizer Treatment for Psoriasis Shows Positive Results in Studies

By Dow Jones Business News, April 22, 2014, 08:53:00 AM EDT

By Tess Stynes

Pfizer Inc. ( PFE ) said two Phase 3 studies to evaluate the effectiveness and safety of its treatment for adults with moderate-to-severe plaque psoriasis showed positive results.

The studies of the twice-daily pill–known as tofacitinib — at two dosing levels was more effective than a placebo in achieving a response of “clear” or “almost clear” at 16 weeks and in the portion of patients achieving at least a 75% reduction in the severity and area affected by psoriasis.

Pfizer plans to submit a supplemental new drug application to the U.S. Food and Drug Administration by early next year.

Tofacitinib — sold domestically under the brand name Xeljanz — is approved in more than 20 countries for adults with hard-to-treat cases of moderate-to-severe rheumatoid arthritis.

Write to Tess Stynes at tess.stynes@wsj.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

See the original post here:
Pfizer Treatment for Psoriasis Shows Positive Results in Studies